secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-08-14T20:05:42+00:00
Accession:  0001104659-26-097091
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis fully enrolls Phase 3 AD trial with 850 patients; Q2 net loss $0.40/share
--------------------------------------------------------------------------------

- Pivotal Phase 3 AD trial fully enrolled with 850 patients, exceeding original target of 760; topline symptomatic data expected Q1 2027.
- PD OLE study enrolled 266 of 500 patients; full enrollment projected Q4 2026; 26 US sites activated.
- Q2 2026 net loss $0.40/share vs $0.32 in Q2 2025; R&D spend $12.0M vs $5.2M YoY.
- Cash $18.7M at June 30, 2026 vs $19.5M at Dec 31, 2025; 42.6M shares outstanding.
- Cheng Fang, Ph.D. promoted to Chief Scientific Officer; AD OLE study to initiate October 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/0001104659-26-097091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-097091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer